Biotech’s Iron Lady: The Story of Dr. Zanganeh

In 2022, she joined Duggan again—this time at Summit Therapeutics. They made headlines by securing a high-stakes deal with China's Akeso for the cancer drug ivonescimab. The deal included a $500 million upfront payment and up to $4.5 billion in milestone payments. Early trial results were highly promising, showing longer remission periods than current leading therapies like Keytruda.